Format

Send to

Choose Destination
Adv Chronic Kidney Dis. 2019 Jul;26(4):253-266. doi: 10.1053/j.ackd.2019.04.004.

Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.

Author information

1
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN.
2
Department of Medicine, Vanderbilt University Medical Center, Nashville, TN; Department of Medical Cell Biology, Uppsala Universitet, Uppsala, Sweden; Department of Molecular Physiology & Biophysics and Program in Cancer Biology, Vanderbilt University School of Medicine, Nashville, TN. Electronic address: volkerhhaase@gmail.com.

Abstract

Prolyl hydroxylase domain oxygen sensors are dioxygenases that regulate the activity of hypoxia-inducible factor (HIF), which controls renal and hepatic erythropoietin production and coordinates erythropoiesis with iron metabolism. Small molecule inhibitors of prolyl hydroxylase domain dioxygenases (HIF-PHI [prolyl hydroxylase inhibitor]) stimulate the production of endogenous erythropoietin and improve iron metabolism resulting in efficacious anemia management in patients with CKD. Three oral HIF-PHIs-daprodustat, roxadustat, and vadadustat-have now advanced to global phase III clinical development culminating in the recent licensing of roxadustat for oral anemia therapy in China. Here, we survey current clinical experience with HIF-PHIs, discuss potential therapeutic advantages, and deliberate over safety concerns regarding long-term administration in patients with renal anemia.

KEYWORDS:

Anemia; Chronic kidney disease; Erythropoietin; Hypoxia-inducible factor; Prolyl hydroxylase domain

PMID:
31477256
DOI:
10.1053/j.ackd.2019.04.004

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center